List of Chapters/Sections(Table Of Content)
1 Study Coverage
1.1 Metabolic Disorder Therapeutics Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Metabolic Disorder Therapeutics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Metabolic Disorder Therapeutics Market Size for the Year 2017-2028
1.2.2 Global Metabolic Disorder Therapeutics Market Size for the Year 2017-2028
1.3 Metabolic Disorder Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Metabolic Disorder Therapeutics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Metabolic Disorder Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Metabolic Disorder Therapeutics Market Dynamics
1.4.1 Metabolic Disorder Therapeutics Industry Trends
1.4.2 Metabolic Disorder Therapeutics Market Drivers
1.4.3 Metabolic Disorder Therapeutics Market Challenges
1.4.4 Metabolic Disorder Therapeutics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Metabolic Disorder Therapeutics by Type
2.1 Metabolic Disorder Therapeutics Market Segment by Type
2.1.1 Lysosomal Storage Diseases
2.1.2 Diabetes
2.1.3 Obesity
2.1.4 Inherited Metabolic Disorders
2.1.5 Hypercholesterolemia
2.2 Global Metabolic Disorder Therapeutics Market Size by Type (2017, 2022 & 2028)
2.3 Global Metabolic Disorder Therapeutics Market Size by Type (2017-2028)
2.4 United States Metabolic Disorder Therapeutics Market Size by Type (2017, 2022 & 2028)
2.5 United States Metabolic Disorder Therapeutics Market Size by Type (2017-2028)
3 Metabolic Disorder Therapeutics by Application
3.1 Metabolic Disorder Therapeutics Market Segment by Application
3.1.1 Oral
3.1.2 Parenteral
3.1.3 Others
3.2 Global Metabolic Disorder Therapeutics Market Size by Application (2017, 2022 & 2028)
3.3 Global Metabolic Disorder Therapeutics Market Size by Application (2017-2028)
3.4 United States Metabolic Disorder Therapeutics Market Size by Application (2017, 2022 & 2028)
3.5 United States Metabolic Disorder Therapeutics Market Size by Application (2017-2028)
4 Global Metabolic Disorder Therapeutics Competitor Landscape by Company
4.1 Global Metabolic Disorder Therapeutics Market Size by Company
4.1.1 Top Global Metabolic Disorder Therapeutics Companies Ranked by Revenue (2021)
4.1.2 Global Metabolic Disorder Therapeutics Revenue by Player (2017-2022)
4.2 Global Metabolic Disorder Therapeutics Concentration Ratio (CR)
4.2.1 Metabolic Disorder Therapeutics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Metabolic Disorder Therapeutics in 2021
4.2.3 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Metabolic Disorder Therapeutics Headquarters, Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Metabolic Disorder Therapeutics Headquarters and Area Served
4.3.2 Global Metabolic Disorder Therapeutics Companies Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Metabolic Disorder Therapeutics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Metabolic Disorder Therapeutics Market Size by Company
4.5.1 Top Metabolic Disorder Therapeutics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Metabolic Disorder Therapeutics Revenue by Players (2020, 2021 & 2022)
5 Global Metabolic Disorder Therapeutics Market Size by Region
5.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Metabolic Disorder Therapeutics Market Size by Region (2017-2028)
5.2.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2017-2022
5.2.2 Global Metabolic Disorder Therapeutics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Metabolic Disorder Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Novo Nordisk A/S
7.1.1 Novo Nordisk A/S Company Details
7.1.2 Novo Nordisk A/S Business Overview
7.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
7.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.1.5 Novo Nordisk A/S Recent Development
7.2 Sanofi S.A.
7.2.1 Sanofi S.A. Company Details
7.2.2 Sanofi S.A. Business Overview
7.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
7.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.2.5 Sanofi S.A. Recent Development
7.3 Boehringer Ingelheim GmbH
7.3.1 Boehringer Ingelheim GmbH Company Details
7.3.2 Boehringer Ingelheim GmbH Business Overview
7.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
7.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.3.5 Boehringer Ingelheim GmbH Recent Development
7.4 Eli Lilly and Company
7.4.1 Eli Lilly and Company Company Details
7.4.2 Eli Lilly and Company Business Overview
7.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
7.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.4.5 Eli Lilly and Company Recent Development
7.5 Merck KgaA
7.5.1 Merck KgaA Company Details
7.5.2 Merck KgaA Business Overview
7.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
7.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.5.5 Merck KgaA Recent Development
7.6 Amgen, Inc.
7.6.1 Amgen, Inc. Company Details
7.6.2 Amgen, Inc. Business Overview
7.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
7.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.6.5 Amgen, Inc. Recent Development
7.7 AstraZeneca PLC
7.7.1 AstraZeneca PLC Company Details
7.7.2 AstraZeneca PLC Business Overview
7.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
7.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.7.5 AstraZeneca PLC Recent Development
7.8 Actelion Pharmaceuticals Ltd.
7.8.1 Actelion Pharmaceuticals Ltd. Company Details
7.8.2 Actelion Pharmaceuticals Ltd. Business Overview
7.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
7.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.8.5 Actelion Pharmaceuticals Ltd. Recent Development
7.9 Shire PLC
7.9.1 Shire PLC Company Details
7.9.2 Shire PLC Business Overview
7.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
7.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.9.5 Shire PLC Recent Development
7.10 AbbVie, Inc.
7.10.1 AbbVie, Inc. Company Details
7.10.2 AbbVie, Inc. Business Overview
7.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
7.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.10.5 AbbVie, Inc. Recent Development
7.11 Biocon Ltd.
7.11.1 Biocon Ltd. Company Details
7.11.2 Biocon Ltd. Business Overview
7.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
7.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.11.5 Biocon Ltd. Recent Development
7.12 BioMarin Pharmaceutical, Inc.
7.12.1 BioMarin Pharmaceutical, Inc. Company Details
7.12.2 BioMarin Pharmaceutical, Inc. Business Overview
7.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
7.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.12.5 BioMarin Pharmaceutical, Inc. Recent Development
7.13 Bristol-Myers Squibb Company
7.13.1 Bristol-Myers Squibb Company Company Details
7.13.2 Bristol-Myers Squibb Company Business Overview
7.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
7.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.13.5 Bristol-Myers Squibb Company Recent Development
7.14 Cipla, Inc.
7.14.1 Cipla, Inc. Company Details
7.14.2 Cipla, Inc. Business Overview
7.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
7.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.14.5 Cipla, Inc. Recent Development
7.15 CymaBay Therapeutics, Inc.
7.15.1 CymaBay Therapeutics, Inc. Company Details
7.15.2 CymaBay Therapeutics, Inc. Business Overview
7.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
7.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.15.5 CymaBay Therapeutics, Inc. Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
